Matthew D. Galsky

Matthew D. Galsky, MD is Professor of Medicine and Director of Genitourinary Medical Oncology at the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai. He is one of the most innovative bladder cancer clinical and translational researchers in the United States, recognized for his leadership in biomarker-driven trial design and for advancing genomics-informed approaches to bladder cancer therapy. Dr. Galsky led the SWOG S1314 (CO-EXPRES) trial, a landmark SWOG cooperative group study that prospectively validated the COXEN (co-expression extrapolation) algorithm as a predictive biomarker for gemcitabine-cisplatin and MVAC neoadjuvant chemotherapy response in muscle-invasive bladder cancer — a major step toward individualizing perioperative chemotherapy selection. He has made seminal contributions to defining split-dose cisplatin regimens as a feasible alternative for borderline-eligible patients, expanding access to cisplatin-based therapy in the advanced urothelial carcinoma population. Dr. Galsky has been a leader in evaluating atezolizumab, pembrolizumab, and nivolumab in cisplatin-ineligible advanced urothelial carcinoma. He leads a highly productive translational research program at Mount Sinai investigating tumor mutational burden, stromal signatures, and immune biomarkers in bladder cancer, and serves on ASCO and NCCN genitourinary cancer guideline panels.